Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026

Analyses explore potential ALS prognostic biomarker and emerging digital health tools for monitoring disease progression

Apr. 17, 2026 at 6:24am

Got story updates? Submit your updates here. ›

An ethereal, ghostly X-ray image revealing the delicate structure of human lungs, conceptually representing the use of advanced medical imaging and digital monitoring to gain deeper insights into the progression of ALS.Cutting-edge digital health tools are helping researchers better understand the progression of amyotrophic lateral sclerosis (ALS) and its impact on respiratory function.Chicago Today

Shionogi Inc. announced two presentations highlighting research in amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 2026 Annual Meeting. The first presentation will assess neutrophil-to-lymphocyte ratio (NLR) changes in response to edaravone oral suspension-treated patients with ALS and examine the predictive value of baseline NLR. The second presentation will evaluate smartphone-based telespirometry as an at-home tool for ALS monitoring, highlighting the importance of incorporating non-invasive ventilation (NIV) use into clinical study design.

Why it matters

These analyses contribute to the ongoing scientific dialogue around ALS, exploring potential biomarkers and digital health tools that could advance monitoring and understanding of disease progression. As a leading rare disease research company, Shionogi's work in ALS aims to provide new treatment options and improve care for patients.

The details

The first presentation will assess neutrophil-to-lymphocyte ratio (NLR) changes in response to edaravone oral suspension-treated patients with ALS, examining the predictive value of baseline NLR compared with propensity score-matched PRO-ACT placebo controls. The second presentation will evaluate a six-month prospective study of patients receiving edaravone, where a smartphone application-mediated, supervised, at-home telespirometry tool identified statistically significant differences in erect and supine slow vital capacity and ALSFRS-R decline based on non-invasive ventilation (NIV) status.

  • The presentations will take place at the AAN 2026 Annual Meeting, which is scheduled for April 18-22 in Chicago, Illinois, and online.
  • The NLR analysis will be presented on April 21 at 4:54 pm CT during the S32: General Neurology 1 session.
  • The digital health study will be presented on April 21 from 8:00 am-9:00 am CT during the P7: General Neurology: Community and Population Studies 2 session.

The players

Shionogi Inc.

An American subsidiary of the global, research-driven pharmaceutical company Shionogi & Co., Ltd., headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients with rare diseases.

Gustavo A. Suarez Zambrano, M.D.

Vice President, Medical Affairs, Rare Disease at Shionogi.

Benjamin Rix Brooks, M.D.

Researcher at Clinical Trials Planning LLC in Charlotte, North Carolina.

Eufrosina I. Young, M.D.

Researcher at SUNY Upstate Medical University.

Got photos? Submit your photos here. ›

What they’re saying

“We look forward to sharing these analyses at AAN and contributing to the ongoing scientific dialogue around ALS.”

— Gustavo A. Suarez Zambrano, M.D., Vice President, Medical Affairs, Rare Disease, Shionogi

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

These analyses from Shionogi highlight the company's commitment to advancing research and understanding of ALS, a devastating neurodegenerative disease with limited treatment options. By exploring potential biomarkers and leveraging digital health tools, Shionogi aims to improve monitoring and care for ALS patients.